Are Psychedelic Drugs More Effective Than Antidepressants?

Select Language:

Recent years have seen a surge of interest in psychedelic-assisted therapy as a potential breakthrough treatment for depression. Substances like psilocybin, commonly known as “magic mushrooms,” and LSD have been explored for their potential to help individuals who don’t respond well to traditional antidepressants. Early research indicated significant benefits, fueling excitement among scientists, healthcare providers, and the public alike.

However, a recent study published on March 18 in JAMA Psychiatry suggests that psychedelics may not be more effective than standard antidepressant medications when evaluated under fair conditions. Depression, or major depressive disorder, is a severe mental health issue affecting millions worldwide. It often results in prolonged feelings of sadness, a loss of interest, low energy levels, and difficulties functioning daily.

While antidepressants are a common treatment, they don’t work for everyone. That has led researchers to seek alternative options. Psychedelic therapy differs from conventional medication in that it generally involves taking a psychedelic drug in a controlled environment with support from trained therapists. Many patients report intense emotional or spiritual experiences, which they believe help them process difficult thoughts and feelings.

Studying these therapies scientifically presents challenges. Clinical trials typically compare a treatment to a placebo—a substance with no active effects. Ideally, neither participants nor researchers know who receives the real treatment versus the placebo, a process called “blinding,” to eliminate bias. Because psychedelics produce noticeable effects, participants can often tell whether they’ve taken the active drug, which can influence outcomes based on their expectations.

To address this problem, researchers from the University of California, San Francisco; UCLA; and Imperial College London developed a new approach. Instead of comparing psychedelic therapy to placebo-controlled antidepressant trials, they compared it to “open-label” antidepressant trials, where participants are aware they are receiving medication, aligning expectations across groups.

Analyzing data from several studies, the researchers found unexpected results. When both treatments were evaluated under similar conditions, their effectiveness was nearly identical. Patients in both groups showed comparable improvements in depression symptoms, with an average reduction of about 12 points on a standard depression scale. This indicates that while both therapies can be helpful, neither clearly outperforms the other.

This outcome surprised many researchers. Dr. Balázs Szigeti, one of the lead authors, anticipated that psychedelic therapy would yield stronger results. Instead, when evaluated more fairly, the previously noted advantages of psychedelic treatments diminished.

The findings suggest that early studies may have overestimated psychedelics’ benefits because participants could often tell which treatment they received. Those who believed they received the real drug might have experienced a placebo effect driven by hope and expectation, while those aware they took a placebo may have felt disappointed. Traditional antidepressant trials tend to show smaller differences between drug and placebo because participants’ expectations are less certain, which actually helps balance the “expectation effect” across treatment types.

While this does not imply that psychedelic therapy is ineffective, it does indicate that its benefits may not exceed those of existing treatments. One limitation of the study is that it compared results from different trials rather than testing both treatment types head-to-head within the same experiment. More direct research is needed to confirm these findings.

Ultimately, the study highlights the importance of rigorous testing for new treatments. Psychedelic therapy remains promising, especially for individuals resistant to traditional treatments, but it may not be the “miracle cure” some have hoped for. Both psychedelic-assisted therapy and conventional antidepressants can provide relief, and the best approach will depend on a person’s unique circumstances, medical history, and preferences. Continued research will help determine how these options can be used safely and effectively.

For those interested in mental health, it’s important to explore studies that identify core features of depression and examine the brain mechanisms involved. Recent research reveals certain metals in the brain are strongly linked to depression. Additionally, current studies are investigating potential risks of drugs that may harm brain health, as well as therapies shown to be more effective than ketamine in treating severe depression.